# From a growth hormone signal to an outcome in people

- Article ID: research-067
- Product: CJC-1295 No DAC (cjc-1295-no-dac-623, cjc-1295-no-dac-520, cjc-1295-no-dac-609)
- Canonical page: https://heritagebiolabs.com/research-library/articles/067-from-a-growth-hormone-signal-to-an-outcome-in-people
- Product collection: https://heritagebiolabs.com/research-library/products/cjc-1295-no-dac
- Product page: https://heritagebiolabs.com/product/cjc-1295-no-dac-623
- Product page: https://heritagebiolabs.com/product/cjc-1295-no-dac-520
- Product page: https://heritagebiolabs.com/product/cjc-1295-no-dac-609
- Reading focus: Mechanisms & biology (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2024

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Short chains of amino acids linked by peptide bonds can work as messages from one tissue to another. CJC-1295 No DAC generally refers to Mod GRF (1–29), a 29-residue analogue designed around the natural signal for growth hormone release. An important research question is how a hormone measurement could be connected to an outcome that matters to people with growth hormone deficiency. [1]

That connection has several steps. First comes the question of whether the precise compound activates the receptor in a controlled experiment. Then researchers can ask whether it changes blood growth hormone concentrations and, over time, changes insulin-like growth factor 1 (IGF-1). IGF-1 is one of the body's downstream responses to growth hormone. Even if those measurements move as expected, a trial designed to evaluate treatment would still need to assess outcomes in people with the condition. [1]

When the FDA evaluated growth hormone deficiency as a proposed use in 2024, it found no clinical effectiveness studies in people with that condition for the CJC-1295 forms it assessed. It also found no human studies of the specific no-DAC free base or its acetate salt. The published human studies it could identify used the DAC active molecule and focused on healthy adults. [1]

No recent primary study was identified here that closes the gap for the no-DAC form. The older regulatory briefing distinguishes the proposed indication from the evidence actually available. A clinical study would need to define who has the condition, choose a relevant comparison group and follow a suitable outcome over time. Short-term changes in a laboratory result would provide one part of that evidence. [1]

## Sources

1. U.S. Food and Drug Administration. December 4, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting. FDA briefing document on CJC-1295-related bulk drug substances (publication 2024-12-04). <https://www.fda.gov/media/183819/download>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 014 - CJC-1295 No DAC and CJC-1295 With DAC.docx; article 67; content SHA-256 22238ea65afa8da3a40d15523a828831cfeab67650c133e2a49e87101fbaf7e5.
